<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Alemtuzumab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Alemtuzumab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Alemtuzumab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Alemtuzumab</b> is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis.<span class="mw-ref" id="cite_ref-AHFS2019_1-0"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> In CLL has been used as both a first line and second line treatment.<span class="mw-ref" id="cite_ref-AHFS2019_1-1"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> In MS it is generally only recommended if other treatments have not worked.<span class="mw-ref" id="cite_ref-AHFS2019_1-2"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is given by injection into a vein.<span class="mw-ref" id="cite_ref-AHFS2019_1-3"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Alemtuzumab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Alemtuzumab_Fab_1CE1.png" tppabs="https://ptable.com/wiki/compounds/I/m/Alemtuzumab_Fab_1CE1.png" data-file-width="1000" data-file-height="1355" data-file-type="bitmap" height="298" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Humanized (from rat)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>CD52</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Campath, MabCampath, Lemtrada, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/alemtuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/alemtuzumab.html'" tppabs="https://www.drugs.com/monograph/alemtuzumab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a608053.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a608053.html'" tppabs="https://medlineplus.gov/druginfo/meds/a608053.html" class="external text external">a608053</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Alemtuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Alemtuzumab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Alemtuzumab" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B2<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous infusion</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AA34<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AA34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AA34'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AA34" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>~288 hrs</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=216503-57-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=216503-57-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=216503-57-0" class="external text external">216503-57-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00087  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00087'" tppabs="https://www.drugbank.ca/drugs/DB00087" class="external text external">DB00087</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=3A189DH42V  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=3A189DH42V'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=3A189DH42V" class="external text external">3A189DH42V</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201587  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201587'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201587" class="external text external">ChEMBL1201587</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6468</sub><span>H</span><sub>10066</sub><span>N</span><sub>1732</sub><span>O</span><sub>2005</sub><span>S</span><sub>40</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">145<span style="margin-left:.25em;">454</span>.20</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477317070&page2=Alemtuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477317070&page2=Alemtuzumab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477317070&page2=Alemtuzumab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.</p>

<p>Alemtuzumab was approved for medical use in the United States in 2001.<span class="mw-ref" id="cite_ref-AHFS2019_1-4"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> (Mab)Campath was withdrawn from the markets in the US and Europe in 2012 to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.<span class="mw-ref" id="cite_ref-pt_2-0"><a href="#cite_note-pt-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_lymphocytic_leukemia">Chronic lymphocytic leukemia</h3></summary>
    
<p>Alemtuzumab is used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in people who have been treated with alkylating agents and who have failed fludarabine therapy. It is an unconjugated antibody, thought to work via the activation of antibody-dependent cell-mediated cytotoxicity (ADCC).<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Multiple_sclerosis">Multiple sclerosis</h3></summary>
    
<p>It is used for the relapsing remitting form of multiple sclerosis.<span class="mw-ref" id="cite_ref-AHFS2019_1-5"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> A 2017 Cochrane meta-analysis of studies comparing alemtuzumab to interferon beta 1a concluded that annual cycles of alemtuzumab probably reduces the proportion of people that experience relapse and may reduce the proportion of people who experience disability worsening and new T2 lesions on MRI, with adverse events found to be similarly high for both treatments.<span class="mw-ref" id="cite_ref-:0_4-0"><a href="#cite_note-:0-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> However the low-to-moderate levels of evidence in the included, existing studies were noted and the need for larger high-quality randomised, double‐blind, controlled trials comparing mono or combination therapy with alemtuzumab was highlighted.<span class="mw-ref" id="cite_ref-:0_4-1"><a href="#cite_note-:0-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It is generally only recommended in people do not respond sufficiently to at least two other MS medications.<span class="mw-ref" id="cite_ref-AHFS2019_1-6"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Alemtuzumab is contraindicated in patients who have active systemic infections, underlying immunodeficiency (e.g., seropositive for HIV), or known Type I hypersensitivity or anaphylactic reactions to the substance.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>In November 2018, the US Food and Drug Administration (FDA) issued a Safety Announcement<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> warning about rare but serious instances of stroke and blood vessel wall tears in multiple sclerosis patients who have received Lemtrada (alemtuzumab), mostly occurring within 1 day of initiating treatment and leading in some cases to permanent disability and even death.</p>

<p>In addition to the 13 cases to which the FDA Safety Announcement refers, a further 5 cases of spontaneous intracranial haemorrhage have been retrospectively identified from four US multiple sclerosis centres in correspondence published online in February 2019.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>On 12 April 2019, the <a href="javascript:if(confirm('https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac'" tppabs="https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac" class="external text external">Pharmacovigilance Risk Assessment Committee</a> (PRAC) of the European Medicines Agency (EMA) reported that it has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions and of problems with the heart and blood vessels with this medicine, including fatal cases. PRAC advised that while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. PRAC further advised that patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>Very common adverse reactions associated with alemtuzumab infusion in MS patients include upper respiratory tract and urinary tract infections, herpes virus infections, lymphopenia, leucopenia, changes in thyroid function, tachycardia, skin rashes, pruritus, pyrexia, and fatigue.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> The Summary of Product Characteristics provided in the electronic Medicines Compendium [eMC <span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span>] further lists common and uncommon adverse reactions that have been reported for Lemtrada, which include serious opportunistic nocardial infections and cytomegalovirus syndrome.<span class="mw-ref" id="cite_ref-Sheikh-Taha2017_10-0"><a href="#cite_note-Sheikh-Taha2017-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Clerico2017_11-0"><a href="#cite_note-Clerico2017-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Brownlee2017_12-0"><a href="#cite_note-Brownlee2017-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Alemtuzumab can also precipitate autoimmune disease through the suppression of regulatory T cell populations and/or the emergence of autoreactive B-cells.<span class="mw-ref" id="cite_ref-Costelloe2012_13-0"><a href="#cite_note-Costelloe2012-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Aranha2013_14-0"><a href="#cite_note-Aranha2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<p>Cases of multiple sclerosis reactivation/relapse have also been reported<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Biochemical_properties">Biochemical properties</h2></summary>
    
<p>Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21–28 kDa cell surface glycoprotein CD52.<span class="mw-ref" id="cite_ref-Klement_16-0"><a href="#cite_note-Klement-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Antiviral_properties">Antiviral properties</h3></summary>
    
<p>In an in-vitro experiment, it has been shown that alemtuzumab has antiviral properties against HIV-1.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>The origins of alemtuzumab date back to <i>Campath-1</i> which was derived from the rat antibodies raised against human lymphocyte proteins by Herman Waldmann and colleagues in 1983.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> The name "Campath" derives from the <i>path</i>ology department of Cambridge University.</p>

<p>Initially, Campath-1 was not ideal for therapy because patients could, in theory, react against the foreign rat protein determinants of the antibody. To circumvent this problem, Greg Winter and his colleagues humanised Campath-1, by extracting the hypervariable loops that had specificity for CD52 and grafting them onto a human antibody framework. This became known as Campath-1H and serves as the basis for alemtuzumab.<span class="mw-ref" id="cite_ref-pmid3127726_19-0"><a href="#cite_note-pmid3127726-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>While alemtuzumab started life as a laboratory tool for understanding the immune system, within a short time it was clinically investigated for use to improve the success of bone marrow transplants and as a treatment for leukaemia, lymphoma, vasculitis, organ transplants, rheumatoid arthritis and multiple sclerosis.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Campath as medication was first approved for B-cell chronic lymphocytic leukemia in 2001. It is marketed by Genzyme, which acquired the worldwide rights from Bayer AG in 2009. Genzyme was bought by Sanofi in 2011. In August/September 2012 Campath was withdrawn from the markets in the US and Europe. This was done to prevent off-label use of the drug to treat multiple sclerosis and to prepare for a relaunch under the trade name <i>Lemtrada</i>, with a different dosage aimed at multiple sclerosis treatment, this is expected to be much higher-priced.<span class="mw-ref" id="cite_ref-pt_2-1"><a href="#cite_note-pt-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<p>Bayer reserves the right to co-promote Lemtrada for 5 years, with the option to renew for an additional five years.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Sanofi_acquisition_and_change_of_license_controversy">Sanofi acquisition and change of license controversy</h3></summary>
    
<p>In February 2011, Sanofi-Aventis, since renamed Sanofi, acquired Genzyme, the manufacturer of alemtuzumab.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span>  The acquisition was delayed by a dispute between the two companies regarding the value of alemtuzumab.  The dispute was settled by the issuance of Contingent Value Rights, a type of stock warrant which pays a dividend only if alemtuzumab reaches certain sales targets.  The contingent value rights (CVR) trade on the NASDAQ-GM market with the ticker symbol GCVRZ.</p>

<p>In August 2012, Genzyme surrendered the licence for all presentations of alemtuzumab,<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> pending regulatory approval to re-introduce it as a treatment for multiple sclerosis. Concerns<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> that Genzyme would later bring to market the same product at a much higher price proved correct.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research_and_off-label_use">Research and off-label use</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Graft-versus-host_disease">Graft-versus-host disease</h3></summary>
    
<p>A 2009 retrospective study of alemtuzumab (10<span>&nbsp;</span>mg IV weekly) in 20 patients (no controls) with severe steroid-resistant acute intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) demonstrated improvement. Overall response rate was 70%, with complete response in 35%.<span class="mw-ref" id="cite_ref-Schn2009_24-0"><a href="#cite_note-Schn2009-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> In this study, the median survival was 280 days.  Important complications following this treatment included cytomegalovirus reactivation, bacterial infection, and invasive aspergillosis infection.<span class="mw-ref" id="cite_ref-Schn2009_24-1"><a href="#cite_note-Schn2009-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-AHFS2019-1"> <span id="mw-reference-text-cite_note-AHFS2019-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/alemtuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/alemtuzumab.html'" tppabs="https://www.drugs.com/monograph/alemtuzumab.html" class="external text external">"Alemtuzumab Monograph for Professionals"</a>. <i>Drugs.com</i>. American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">15 July</span> 2019</span>.</cite></span></li><li id="cite_note-pt-2"> <span id="mw-reference-text-cite_note-pt-2" class="mw-reference-text"><cite id="CITEREFMcKee,_Selina2012" class="citation news cs1">McKee, Selina (21 August 2012). <a href="javascript:if(confirm('http://www.pharmatimes.com/Article/12-08-21/Sanofi_withdraws_Campath_in_US_and_EU.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmatimes.com/Article/12-08-21/Sanofi_withdraws_Campath_in_US_and_EU.aspx'" tppabs="http://www.pharmatimes.com/Article/12-08-21/Sanofi_withdraws_Campath_in_US_and_EU.aspx" class="external text external">"Sanofi withdraws Campath in US and EU"</a>. <i>Pharma Times Online</i>. Pharma Times.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html'" tppabs="https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html" class="external text external">"About Campath"</a>. Genzyme. Archived from <a href="javascript:if(confirm('http://www.campath.com/hcp/AboutCampath.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.campath.com/hcp/AboutCampath.html'" tppabs="http://www.campath.com/hcp/AboutCampath.html" class="external text external">the original</a> on 2011-07-14.</cite></span></li><li id="cite_note-:0-4"> <span id="mw-reference-text-cite_note-:0-4" class="mw-reference-text"><cite id="CITEREFZhangShiZhangLuo2017" class="citation journal cs1">Zhang, Jian; Shi, Shengliang; Zhang, Yueling; Luo, Jiefeng; Xiao, Yousheng; Meng, Lian; Yang, Xiaobo (27 November 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233" class="external text external">"Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>11</b>: CD010968. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD010968.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD010968.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD010968.pub2" class="external text external">10.1002/14651858.CD010968.pub2</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486233" class="external text external">6486233</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29178444  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29178444'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29178444" class="external text external">29178444</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf" class="external free external">https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf</a></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFAzevedo_CJKutz_CDix_ABoster_A2019" class="citation journal cs1">Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J (2019). <a href="javascript:if(confirm('https://doi.org/10.1016/S1474-4422(19)30076-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/S1474-4422(19)30076-6'" tppabs="https://doi.org/10.1016/S1474-4422(19)30076-6" class="external text external">"Intracerebral haemorrhage during alemtuzumab administration"</a>. <i>The Lancet. Neurology</i>. <b>18</b> (4): 329–331. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2FS1474-4422%2819%2930076-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1474-4422%2819%2930076-6'" tppabs="https://doi.org/10.1016%2FS1474-4422%2819%2930076-6" class="external text external">10.1016/S1474-4422(19)30076-6</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30777657  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30777657'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30777657" class="external text external">30777657</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019'" tppabs="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019" class="external free external">https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019</a></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/5409  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/5409#UNDESIRABLE_EFFECTS'" tppabs="https://www.medicines.org.uk/emc/product/5409#UNDESIRABLE_EFFECTS" class="external free external">https://www.medicines.org.uk/emc/product/5409#UNDESIRABLE_EFFECTS</a></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/'" tppabs="https://www.medicines.org.uk/emc/" class="external free external">https://www.medicines.org.uk/emc/</a></span></li><li id="cite_note-Sheikh-Taha2017-10"> <span id="mw-reference-text-cite_note-Sheikh-Taha2017-10" class="mw-reference-text"><cite id="CITEREFSheikh-Taha_MCorman_LC2017" class="citation journal cs1">Sheikh-Taha M; Corman LC (2017). "Pulmonary <i>Nocardia beijingensis</i> infection associated with the use of alemtuzumab in a patient with multiple sclerosis". <i>Multiple Sclerosis Journal</i>. <b>23</b> (6): 872–874. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1352458517694431  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1352458517694431'" tppabs="https://doi.org/10.1177%2F1352458517694431" class="external text external">10.1177/1352458517694431</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28290754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28290754'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28290754" class="external text external">28290754</a>.</cite></span></li><li id="cite_note-Clerico2017-11"> <span id="mw-reference-text-cite_note-Clerico2017-11" class="mw-reference-text"><cite id="CITEREFClerico_MDe_Mercanti_SArtusi_CADurelli_L2017" class="citation journal cs1">Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT (2017). "Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab". <i>Multiple Sclerosis Journal</i>. <b>23</b> (6): 874–876. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1352458516688350  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1352458516688350'" tppabs="https://doi.org/10.1177%2F1352458516688350" class="external text external">10.1177/1352458516688350</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28290755  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28290755'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28290755" class="external text external">28290755</a>.</cite></span></li><li id="cite_note-Brownlee2017-12"> <span id="mw-reference-text-cite_note-Brownlee2017-12" class="mw-reference-text"><cite id="CITEREFBrownlee_WJChataway_J2017" class="citation journal cs1">Brownlee WJ; Chataway J (2017). <a href="javascript:if(confirm('http://discovery.ucl.ac.uk/1537542/7/Brownlee_Clinical%20commentary_Opportunistic%20infections%20after%20alemtuzumab_Final.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://discovery.ucl.ac.uk/1537542/7/Brownlee_Clinical%20commentary_Opportunistic%20infections%20after%20alemtuzumab_Final.pdf'" tppabs="http://discovery.ucl.ac.uk/1537542/7/Brownlee_Clinical%20commentary_Opportunistic%20infections%20after%20alemtuzumab_Final.pdf" class="external text external">"Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome"</a> <span class="cs1-format">(PDF)</span>. <i>Multiple Sclerosis Journal</i>. <b>23</b> (6): 876–877. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1352458517693440  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1352458517693440'" tppabs="https://doi.org/10.1177%2F1352458517693440" class="external text external">10.1177/1352458517693440</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28290753  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28290753'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28290753" class="external text external">28290753</a>.</cite></span></li><li id="cite_note-Costelloe2012-13"> <span id="mw-reference-text-cite_note-Costelloe2012-13" class="mw-reference-text"><cite id="CITEREFCostelloe_LJones_JColes_A2012" class="citation journal cs1">Costelloe L; Jones J; Coles A (2012). "Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis". <i>Expert Review of Neurotherapeutics</i>. <b>12</b> (3): 335–341. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2Fern.12.5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2Fern.12.5'" tppabs="https://doi.org/10.1586%2Fern.12.5" class="external text external">10.1586/ern.12.5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22364332  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22364332'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22364332" class="external text external">22364332</a>.</cite></span></li><li id="cite_note-Aranha2013-14"> <span id="mw-reference-text-cite_note-Aranha2013-14" class="mw-reference-text"><cite id="CITEREFAranha_AAAmer_SReda_ESBroadley_SA2013" class="citation journal cs1">Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM (2013). "Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review". <i>Endocrine Practice</i>. <b>19</b> (5): 821–828. doi:<a href="javascript:if(confirm('https://doi.org/10.4158%2FEP13020.RA  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4158%2FEP13020.RA'" tppabs="https://doi.org/10.4158%2FEP13020.RA" class="external text external">10.4158/EP13020.RA</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23757618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23757618'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23757618" class="external text external">23757618</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFWehrum_TBeume_L-AStich_OMader_I2018" class="citation journal cs1">Wehrum T; Beume L-A; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S (2018). "Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis". <i>Neurology</i>. <b>90</b> (7): e601–e605. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0000000000004950  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0000000000004950'" tppabs="https://doi.org/10.1212%2FWNL.0000000000004950" class="external text external">10.1212/WNL.0000000000004950</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29352101  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29352101'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29352101" class="external text external">29352101</a>.</cite></span></li><li id="cite_note-Klement-16"> <span id="mw-reference-text-cite_note-Klement-16" class="mw-reference-text"><cite id="CITEREFA._Klement2014" class="citation journal cs1">A. Klement (7 January 2014). "Multiple-Sklerose-Behandlung". <i>Österreichische Apothekerzeitung</i> (in German) (1/2014): 24f.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFRuxrungthamSirivichayakulBuranapraditkunKrause2016" class="citation journal cs1">Ruxrungtham, K; Sirivichayakul, S; Buranapraditkun, S; Krause, W (2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689" class="external text external">"Alemtuzumab-induced elimination of HIV-1-infected immune cells"</a>. <i>Journal of Virus Eradication</i>. <b>2</b> (1): 12–8. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946689" class="external text external">4946689</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27482429  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27482429'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27482429" class="external text external">27482429</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFHaleBrightChumbley1983" class="citation journal cs1">Hale G, Bright S, Chumbley G,  et al. (October 1983). <a href="javascript:if(confirm('https://doi.org/10.1182/blood.V62.4.873.873  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182/blood.V62.4.873.873'" tppabs="https://doi.org/10.1182/blood.V62.4.873.873" class="external text external">"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement"</a>. <i>Blood</i>. <b>62</b> (4): 873–82. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood.V62.4.873.873  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood.V62.4.873.873'" tppabs="https://doi.org/10.1182%2Fblood.V62.4.873.873" class="external text external">10.1182/blood.V62.4.873.873</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6349718  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6349718'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6349718" class="external text external">6349718</a>.</cite></span></li><li id="cite_note-pmid3127726-19"> <span id="mw-reference-text-cite_note-pmid3127726-19" class="mw-reference-text"><cite id="CITEREFRiechmannClarkWaldmannWinter1988" class="citation journal cs1">Riechmann, Lutz; Clark, Michael; Waldmann, Herman; Winter, Greg (1988). "Reshaping human antibodies for therapy". <i>Nature</i>. <b>332</b> (6162): 323–7. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/1988Natur.332..323R  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/1988Natur.332..323R'" tppabs="https://ui.adsabs.harvard.edu/abs/1988Natur.332..323R" class="external text external">1988Natur.332..323R</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F332323a0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F332323a0'" tppabs="https://doi.org/10.1038%2F332323a0" class="external text external">10.1038/332323a0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3127726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3127726'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3127726" class="external text external">3127726</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.whatisbiotechnology.org/exhibitions/campath  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.whatisbiotechnology.org/exhibitions/campath'" tppabs="http://www.whatisbiotechnology.org/exhibitions/campath" class="external text external">"The life story of a biotechnology drug: Alemtuzumab"</a>. What is Biotechnology?.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFWhalen,_JeanneSpencer,_Mimosa2011" class="citation news cs1">Whalen, Jeanne; Spencer, Mimosa (17 February 2011). <a href="javascript:if(confirm('https://www.wsj.com/articles/SB10001424052748703373404576147483489656732  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/SB10001424052748703373404576147483489656732'" tppabs="https://www.wsj.com/articles/SB10001424052748703373404576147483489656732" class="external text external">"Sanofi Buys Genzyme for over $20 billion"</a>. <i>The Wall Street Journal</i>.</cite><span style="font-size:0.95em; font-size:90%; color:#555">(subscription required)</span></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFHussein,_Jasmin_(Genzyme)2012" class="citation web cs1">Hussein, Jasmin (Genzyme) (9 August 2012). <a href="javascript:if(confirm('http://www.medicinesresources.nhs.uk/upload/documents/News/2012/Sanofil%20letter.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicinesresources.nhs.uk/upload/documents/News/2012/Sanofil%20letter.pdf'" tppabs="http://www.medicinesresources.nhs.uk/upload/documents/News/2012/Sanofil%20letter.pdf" class="external text external">"Discontinuation of licensed supplies of alemtuzumab (Mabcampath)"</a> <span class="cs1-format">(PDF)</span>. United Kingdom: National Institute for Health and Care Excellence.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.bbc.co.uk/news/health-20151891  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bbc.co.uk/news/health-20151891'" tppabs="https://www.bbc.co.uk/news/health-20151891" class="external text external">"Multiple sclerosis: New drug 'most effective<span class="cs1-kern-right">'</span>"</a>. <i>BBC News</i>. 1 November 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">1 November</span> 2012</span>.</cite></span></li><li id="cite_note-Schn2009-24"> <span id="mw-reference-text-cite_note-Schn2009-24" class="mw-reference-text"><cite id="CITEREFSchnitzlerHasskarlEggerBertz2009" class="citation journal cs1">Schnitzler, Marc; Hasskarl, Jens; Egger, Matthias; Bertz, Hartmut; Finke, Jürgen (2009). <a href="javascript:if(confirm('https://doi.org/10.1016/j.bbmt.2009.04.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.bbmt.2009.04.002'" tppabs="https://doi.org/10.1016/j.bbmt.2009.04.002" class="external text external">"Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab"</a>. <i>Biology of Blood and Marrow Transplantation</i>. <b>15</b> (8): 910–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bbmt.2009.04.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bbmt.2009.04.002'" tppabs="https://doi.org/10.1016%2Fj.bbmt.2009.04.002" class="external text external">10.1016/j.bbmt.2009.04.002</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19589480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19589480'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19589480" class="external text external">19589480</a>.</cite><span style="position:relative; top: -2px;"><figure-inline><img src="../I/m/Open_Access_logo_PLoS_transparent.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Open_Access_logo_PLoS_transparent.svg.png" data-file-width="640" data-file-height="1000" data-file-type="drawing" height="14" width="9"></figure-inline></span></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('https://web.archive.org/web/20080516053252/http://berlex.bayerhealthcare.com/html/products/pi/Campath_PI.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080516053252/http://berlex.bayerhealthcare.com/html/products/pi/Campath_PI.pdf'" tppabs="https://web.archive.org/web/20080516053252/http://berlex.bayerhealthcare.com/html/products/pi/Campath_PI.pdf" class="external text external">Full Prescribing Information</a></li>
<li><a href="javascript:if(confirm('http://users.path.ox.ac.uk/~scobbold/tig/CAMPATH/CAMPHIST.HTM  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://users.path.ox.ac.uk/~scobbold/tig/CAMPATH/CAMPHIST.HTM'" tppabs="http://users.path.ox.ac.uk/~scobbold/tig/CAMPATH/CAMPHIST.HTM" class="external text external">From laboratory to clinic: the story of CAMPATH-1 (Geoff Hale and Herman Waldmann)</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em">Monoclonal antibodies for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">Tumor<br></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adecatumumab<sup>§</sup></li>
<li>Ascrinvacumab<sup>§</sup></li>
<li>Atezolizumab</li>
<li>Cixutumumab<sup>§</sup></li>
<li>Conatumumab<sup>§</sup></li>
<li>Daratumumab</li>
<li>Drozitumab<sup>§</sup></li>
<li>Duligotumab<sup>§</sup></li>
<li>Dusigitumab<sup>§</sup></li>
<li>Enfortumab vedotin<sup>†</sup></li>
<li>Enoticumab<sup>§</sup></li>
<li>Figitumumab<sup>§</sup></li>
<li>Ganitumab<sup>†</sup></li>
<li>Glembatumumab vedotin<sup>†</sup></li>
<li>Intetumumab<sup>§</sup></li>
<li>Ipilimumab</li>
<li>Iratumumab<sup>§</sup></li>
<li>Istiratumab</li>
<li>Icrucumab<sup>§</sup></li>
<li>Lexatumumab<sup>§</sup></li>
<li>Lucatumumab<sup>§</sup></li>
<li>Mapatumumab<sup>§</sup></li>
<li>Narnatumab<sup>§</sup></li>
<li>Necitumumab</li>
<li>Nesvacumab<sup>§</sup></li>
<li>Nivolumab<sup>#</sup></li>
<li>Ofatumumab</li>
<li>Olaratumab<sup>†</sup></li>
<li>Panitumumab</li>
<li>Patritumab<sup>§</sup></li>
<li>Pembrolizumab<sup>#</sup></li>
<li>Pritumumab<sup>§</sup></li>
<li>Radretumab<sup>§</sup></li>
<li>Ramucirumab</li>
<li>Rilotumumab<sup>†</sup></li>
<li>Robatumumab<sup>§</sup></li>
<li>Seribantumab<sup>§</sup></li>
<li>Tarextumab<sup>§</sup></li>
<li>Teprotumumab<sup>†</sup></li>
<li>Tovetumab<sup>§</sup></li>
<li>Vantictumab<sup>§</sup></li>
<li>Votumumab<sup>§</sup></li>
<li>Zalutumumab<sup>†</sup></li></ul>

<dl><dt><span class="nobold">"-melu-" (melanoma)</span></dt>
<dd>Flanvotumab<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altumomab pentetate</li>
<li>Anatumomab mafenatox</li>
<li><a href="Technetium_(99mTc)_arcitumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li>
<li>Bectumomab</li>
<li>Blinatumomab</li>
<li>Detumomab</li>
<li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li>
<li>Lilotomab</li>
<li>Minretumomab</li>
<li>Mitumomab</li>
<li>Moxetumomab pasudotox</li>
<li>Naptumomab estafenatox</li>
<li>Nofetumomab merpentan</li>
<li>Pemtumomab<sup>†</sup></li>
<li>Pintumomab</li>
<li>Racotumomab</li>
<li><a href="Indium_(111In)_satumomab_pendetide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li>
<li>Solitomab</li>
<li>Taplitumomab paptox</li>
<li>Tenatumomab</li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li>
<li>3F8</li></ul>

<dl><dt><span class="nobold">"-govo-" (ovarian tumor)</span></dt>
<dd>Abagovomab</dd>
<dd>Igovomab</dd>
<dd>Oregovomab</dd></dl>

<dl><dt><span class="nobold">"-pro-" (prostate tumor)</span></dt>
<dd>Capromab pendetide</dd></dl>

<dl><dt><span class="nobold">"-colo-" (colonic tumor)</span></dt>
<dd>Edrecolomab</dd>
<dd>Nacolomab tafenatox</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amatuximab<sup>§</sup></li>
<li>Bavituximab<sup>§</sup></li>
<li>Brentuximab vedotin</li>
<li>Carotuximab<sup>†</sup></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Derlotuximab biotin<sup>§</sup></li>
<li>Dinutuximab</li>
<li>Ensituximab<sup>§</sup></li>
<li>Futuximab<sup>§</sup></li>
<li>Girentuximab<sup>†</sup></li>
<li>Indatuximab ravtansine<sup>§</sup></li>
<li>Isatuximab</li>
<li>Loncastuximab tesirine</li>
<li>Margetuximab<sup>†</sup></li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li>
<li>Siltuximab</li>
<li>Ublituximab<sup>†</sup></li>
<li>IMAB362</li></ul>

<p>"-mexi-" (melanoma): Ecromeximab<sup>§</sup></p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abituzumab<sup>§</sup></li>
<li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li>Belantamab mafodotin</li>
<li>Bevacizumab</li>
<li>Bivatuzumab mertansine<sup>§</sup></li>
<li>Brontictuzumab<sup>§</sup></li>
<li>Cantuzumab mertansine<sup>§</sup></li>
<li>Cantuzumab ravtansine<sup>§</sup></li>
<li>Cirmtuzumab</li>
<li>Citatuzumab bogatox<sup>§</sup></li>
<li>Clivatuzumab tetraxetan</li>
<li>Cofetuzumab pelidotin</li>
<li>Dacetuzumab<sup>§</sup></li>
<li>Demcizumab<sup>§</sup></li>
<li>Dalotuzumab<sup>§</sup></li>
<li>Denintuzumab mafodotin<sup>§</sup></li>
<li>Elotuzumab</li>
<li>Emactuzumab<sup>§</sup></li>
<li>Emibetuzumab<sup>§</sup></li>
<li>Enoblituzumab<sup>§</sup></li>
<li>Etaracizumab<sup>§</sup></li>
<li>Farletuzumab<sup>§</sup></li>
<li>Ficlatuzumab<sup>§</sup></li>
<li>Flotetuzumab<sup>§</sup></li>
<li>Gemtuzumab ozogamicin</li>
<li>Imgatuzumab<sup>§</sup></li>
<li>Inotuzumab ozogamicin<sup>†</sup></li>
<li>Labetuzumab<sup>§</sup></li>
<li>Lifastuzumab vedotin<sup>§</sup></li>
<li>Lintuzumab<sup>§</sup></li>
<li>Lorvotuzumab mertansine<sup>§</sup></li>
<li>Lumretuzumab<sup>§</sup></li>
<li>Matuzumab<sup>§</sup></li>
<li>Milatuzumab<sup>§</sup></li>
<li>Nimotuzumab<sup>†</sup></li>
<li>Obinutuzumab</li>
<li>Ocaratuzumab<sup>§</sup></li>
<li>Otlertuzumab<sup>§</sup></li>
<li>Onartuzumab<sup>§</sup></li>
<li>Oportuzumab monatox<sup>†</sup></li>
<li>Parsatuzumab<sup>§</sup></li>
<li>Pertuzumab</li>
<li>Pinatuzumab vedotin<sup>§</sup></li>
<li>Polatuzumab vedotin<sup>†</sup></li>
<li>Rosmantuzumab</li>
<li>Rovalpituzumab tesirine<sup>†</sup></li>
<li>Sacituzumab govitecan</li>
<li>Sibrotuzumab<sup>§</sup></li>
<li>Simtuzumab<sup>§</sup></li>
<li>Tacatuzumab tetraxetan<sup>§</sup></li>
<li>Tigatuzumab<sup>§</sup></li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup></li>
<li>Tucotuzumab celmoleukin<sup>§</sup></li>
<li>Vandortuzumab vedotin<sup>§</sup></li>
<li>Vanucizumab<sup>§</sup></li>
<li>Veltuzumab<sup>§</sup></li>
<li>Vorsetuzumab mafodotin<sup>§</sup></li>
<li>CBR96-doxorubicin immunoconjugate</li>
<li>PankoMab</li></ul>

<dl><dt><span class="nobold">"-gozu-" (ovarian tumor)</span></dt>
<dd>Sofituzumab vedotin<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Rat/mouse hybrid<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Catumaxomab</li>
<li>Ertumaxomab<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized<br></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Depatuxizumab mafodotin<sup>†</sup></li>
<li>Duvortuxizumab</li>
<li>Ontuxizumab<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>


<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-06-19" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Alemtuzumab&oldid=963401852  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Alemtuzumab&oldid=963401852'" tppabs="https://en.wikipedia.org/wiki/?title=Alemtuzumab&oldid=963401852">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>